VINCENT MED (01612) announces annual performance, with shareholders' profit reaching 104 million Hong Kong dollars, a year-on-year increase of 50.91%. Final dividend per share is 2.6 Hong Kong cents.

VINCENT MED (01612) announced its annual performance ending on December 31, 2025. The group achieved a revenue of HK$933 million, representing a year-on-year increase of 16.46%. The profit attributable to owners of the company amounted to HK$104 million, a 50.91% increase compared to the previous year. Basic earnings per share were 16.18 HK cents, and a final dividend of 2.6 HK cents per share is proposed. The group's Imaging Disposable Products Division maintained its momentum with stable revenue growth. By increasing existing product line orders and deepening long-term partnerships with its key customers (a global leader in the diagnostic imaging market), the division also made significant progress in new business cooperation during the year. On the other hand, the group's Respiratory Products Division showed stable revenue performance, indicating a gradual recovery in demand in a cautious procurement environment. As respiratory care is essential and ongoing, there continues to be demand for related products in clinical and home care settings. Although moderate short-term growth is expected in this division, it still plays an important role in the group's revenue structure and product portfolio. Relying on its strong manufacturing capabilities and accumulated technical expertise, the group actively expanded its product range to include new categories. With broader product supply, expanding distribution networks, and increasing market acceptance, the performance of the group's Health Care and Wellness Products Division, as well as other product divisions, remains stable. This diversification strategy not only opens up new revenue sources but also contributes to improving capacity utilization and operational efficiency.